cannot work traders out..., page-105

Centurione

You are perfectly correct that the grant goes to the Fraunhofer Inst, but that was money that PRR would have had to spend in any event, so the net effect is the same.

True, funding for other jurisdictions comes directly from PRR's coffers, however they have recently made significant changes to reduce the cash burn rate (as explained above).

Nasdaq listing was not done to raise capital as has been explained many times.

It's a given that there will be a need for additional cash to fund commercialisation of CVAC e.g. ramp up of manufacturing and marketing, but that's contingent upon successful trial results and FDA approval.